3-cyanopyridine trifluoroacetate | 81675-55-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-cyanopyridine trifluoroacetate
• 英文别名: Pyridine-3-carbonitrile;2,2,2-trifluoroacetic acid
• CAS: 81675-55-0
• 化学式: C₂HF₃O₂*C₆H₄N₂
• 分子量: 218.135
• InChiKey: ILAILUUAUWUQNG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.33
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  78.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3-氰基吡啶 、 三氟乙酸 以 氯仿 为溶剂， 生成 3-cyanopyridine trifluoroacetate
  参考文献：
  名称：

  氢卤化吡啶鎓盐的氢键物种。2.在非质子传递溶剂中的测温行为

  摘要：

  DOI：

  10.1021/j150656a044
• 作为试剂：
  描述：

  、 phosphoramidochloridic acid, N,N-dimethyl-, [6-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)-4-(triphenylmethyl)-2-morpholinyl]methyl ester 在 N-乙基吗啉 、 lithium bromide 、 3-cyanopyridine trifluoroacetate 、 ammonium hydroxide 作用下， 以 1,3-二甲基-2-咪唑啉酮 、 二氯甲烷 、 2,2,2-三氟乙醇 为溶剂， 反应 1.05h， 以45%的产率得到C₂₂H₃₄N₇O₉P
  参考文献：
  名称：

  Development of an efficient method for phosphorodiamidate bond formation by using inorganic salts

  摘要：

  Phosphorodiamidate morpholino oligonucleotides (PMOs) have been extensively applied in antisense strategies for gene regulation because of their high stability in serum and low toxicity. However, chain elongation of PMOs requires long reaction time because few efficient methods have been developed for the formation of phosphorodiamidate bonds. In this Letter, we examined the effect of various additives to improve the reaction efficiency for formation of the phosphorodiamidate bond in the synthesis of PMOs. The addition of certain inorganic salts to the reaction media was found to be more effective. Particularly, lithium bromide was the most effective reagent and led to considerable acceleration (ca. 10-fold improvement). (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.12.021

文献信息

• SYNTHESIS OF MORPHOLINO OLIGOMERS USING DOUBLY PROTECTED GUANINE MORPHOLINO SUBUNITS
  申请人：REEVES MATTHEW DALE

  公开号：US20090131624A1

  公开（公告）日：2009-05-21

  Morpholino compounds are provided having the structure: where R 1 is selected from the group consisting of lower alkyl, di(lower alkyl)amino, and phenyl; R 2 is selected from the group consisting of lower alkyl, monocyclic arylmethyl, and monocyclic (aryloxy)methyl; R 3 is selected from the group consisting of triarylmethyl and hydrogen; and Y is selected from the group consisting of: a protected or unprotected hydroxyl or amino group; a chlorophosphoramidate group; and a phosphorodiamidate linkage to the ring nitrogen of a further morpholino compound or a morpholino oligomer. Such compounds include doubly protected morpholino guanine (MoG) monomers. Also described is their use in synthesis of morpholino oligomers.

  Morpholino化合物具有以下结构： 其中 R1选自由较低烷基、二(较低烷基)氨基和苯基组成的群体； R2选自由较低烷基、单环芳基甲基和单环(芳氧基)甲基组成的群体； R3选自由三芳基甲基和氢原子组成的群体；以及 Y选自由受保护或未受保护的羟基或氨基团；氯磷酰胺基团；以及与另一种morpholino化合物或morpholino寡聚体的环氮原子形成磷酰二胺酸酯键的群体。这类化合物包括双保护的morpholino鸟嘌呤（MoG）单体。还描述了它们在morpholino寡聚体合成中的用途。
• [EN] HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE KINASE, COMPOSITIONS COMPRENANT LE COMPOSÉ HÉTÉROCYCLIQUE, ET LEURS PROCÉDÉS D'UTILISATION
  申请人：JS INNOPHARM SHANGHAI LTD

  公开号：WO2020248972A1

  公开（公告）日：2020-12-17

  (I) Disclosed herein are compounds of formula I, and/or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate thereof; and therapeutic uses of these compounds, which are inhibitors of rearranged during transfection (RET), potentially useful in the treatment of RET-associated diseases, such as RET-associated cancers.

  披露了公式I的化合物，以及/或其立体异构体、稳定同位素或药用可接受的盐或溶剂化物；以及这些化合物的治疗用途，这些化合物是转染过程中重排（RET）的抑制剂，可能在治疗RET相关疾病，如RET相关癌症中有潜在用途。
• METHOD OF SYNTHESIS OF MORPHOLINO OLIGOMERS
  申请人：Fox Christina Mary Josephine

  公开号：US20090131632A1

  公开（公告）日：2009-05-21

  Improved methods are described for solid-phase synthesis of morpholino oligomers, in which a protected morpholino ring nitrogen is deprotected between coupling steps using a heterocyclic amine salt in a trifluoroethanol-containing solvent, where the salt is a salt of a heterocyclic amine, having a pKa in the range of 1-4 in its protonated form, with an acid selected from a sulfonic acid, trifluoroacetic acid, and hydrochloric acid. Examples are 3-chloropyridinium methanesulfonate (CPM) and 4-cyanopyridinium trifluoroacetate (CYTFA).

  本文描述了改进的固相合成吗啡基诺寡聚体的方法，其中在使用三氟乙醇溶剂含有杂环胺盐的偶联步骤之间去保护的吗啡基诺环氮原子，其中盐是一种杂环胺盐，其质子化形式的pKa在1-4的范围内，与从磺酸，三氟乙酸和盐酸中选择的酸反应。例如，3-氯吡啶甲磺酸盐（CPM）和4-氰吡啶三氟乙酸盐（CYTFA）是例子。
• RET SELECTIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF
  申请人：Shouyao Holdings (Beijing) Co., Ltd.

  公开号：EP3998265A1

  公开（公告）日：2022-05-18

  The present invention provides an RET selective inhibitor and preparation method and use thereof; the present invention provides a compound of formula (I) and a pharmaceutically accepted salt, solvate, polymorph, or tautomer thereof, a composition comprising these compounds, and use of these compounds in the treatment of diseases related to RET.

  本发明提供了一种RET选择性抑制剂及其制备方法和用途；本发明提供了一种式（I）化合物及其药学上可接受的盐、溶解物、多晶型物或同系物，一种包含这些化合物的组合物，以及这些化合物在治疗与RET有关的疾病中的用途。
• [EN] SUBSTITUTED PYRAZOLE FUSED RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF<br/>[FR] DÉRIVÉ CYCLIQUE CONDENSÉ À UN PYRAZOLE SUBSTITUÉ, SON PROCÉDÉ DE PRÉPARATION ET APPLICATION ASSOCIÉE<br/>[ZH] 取代吡唑稠环类衍生物及其制备方法和应用
  申请人：APPLIED PHARMACEUTICAL SCIENCE INC

  公开号：WO2020064009A1

  公开（公告）日：2020-04-02

  涉及药物化学领域，主要涉及式I所示的化合物、其立体异构体、消旋体、互变异构体、同位素标记物、氮氧化物、或其药学上可接受的盐及其制备方法和在制备用于治疗RET激酶介导的疾病的药物中的用途。